Skip to main content

Table 3 Example 2 Results. Predicted sojourn times and mortality for patients in data example from Grein et al. [9] at 28 days of follow-up. Start: time of treatment initiation, Non-MV: noninvasive positive pressure ventilation, nasal high-flow oxygen therapy, low-flow oxygen, and ambient air, MV: ECMO and MV (): 95% confidence interval for duration estimates, (): standard error for risk estimates

From: Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach

 

53 patients with severe COVID-19 treated with Remdesivir (Grein et al.), results at day 28

Non-MV Duration in Days

MV Duration in Days

Total Length of ICU Stay in Days

Death Risk

Start Non-MV

16.26 (13.87, 18.56)

1.41 (0.27, 2.96)

17.67 (14.14, 21.52)

6.2% (3.3)

Start MV

6.14 (3.86, 8.41)

14.57 (11.99, 17.31)

20.71 (15.85, 25.72)

19.8% (6.4)

Full Cohort

9.77 (7.76, 11.81)

9.85 (7.68, 12.14)

19.62 (15.44, 23.95)

15.0% (5.3)